Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN7409 in advanced or metastatic malignancy
NCT04635995Phase 1Completed
- Sponsor
- Lijin Biomedical Technology
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LVGN7409 in cancer, sponsored by Lijin Biomedical Technology. Primary endpoints: Treatment-Emergent Adverse Events at 24 months and Recommended Phase 2 Dose at 24 months. Started Dec 2020; status: completed.
02
Drugs
LVGN7409
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04635995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635995.